Literature DB >> 10506642

Current status of oral anticancer drugs in Japan.

Y Fujiwara.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10506642     DOI： 10.1200/JCO.1999.17.10.3362

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Clinical trials and the new good clinical practice guideline in Japan. An economic perspective.

Authors:  S Ono; Y Kodama
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

2.  Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Authors:  Anna Vavrova; Hana Jansova; Eliska Mackova; Miloslav Machacek; Pavlina Haskova; Lucie Tichotova; Martin Sterba; Tomas Simunek
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

3.  Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.

Authors:  Khalid O Alfarouk; Christian-Martin Stock; Sophie Taylor; Megan Walsh; Abdel Khalig Muddathir; Daniel Verduzco; Adil H H Bashir; Osama Y Mohammed; Gamal O Elhassan; Salvador Harguindey; Stephan J Reshkin; Muntaser E Ibrahim; Cyril Rauch
Journal:  Cancer Cell Int       Date:  2015-07-15       Impact factor: 5.722
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.